REFERENCES
- West S K. Looking forward to 20/20: a focus on the epidemiology of eye diseases. Epidemiol Rev 2000; 22: 64–70
- Birngruber R, Hillenkamp F, Gabel V P. Theoretical investigations of laser thermal retinal injury. Health Phys 1985; 48: 781–796
- Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 1991; 109: 1220–1231
- Scott L J, Goa K L. Verteporfin. Drugs Aging 2000; 16: 139–146
- Miller J W, Walsh A W, Kramer M, Hasan T, Michaud N, Flotte T J, Haimovici R, Gragoudas E S. Photodynamic therapy of experimental choroidal neovascularization using lipoprotein-delivered benzoporphyrin. Arch Ophthalmol 1995; 113: 810–818
- Husain D, Kramer M, Kenny A G, Michaud N, Flotte T J, Gragoudas E S, Miller J W. Effects of photodynamic therapy using verteporfin on experimental choroidal neovascularization and normal retina and choroid up to 7 weeks after treatment. Invest Ophthalmol Vis Sci 1999; 40: 2322–2331
- Schmidt-Erfurth U, Laqua H, Schlotzer-Schrehard U, Viestenz A, Naumann G O. Histopathological changes following photodynamic therapy in human eyes. Arch Ophthalmol 2002; 120: 835–844
- Reinke M H, Canakis C, Husain D, Michaud N, Flotte T J, Gragoudas E S, Miller J W. Verteporfin photodynamic therapy retreatment of normal retina and choroid in the cynomolgus monkey. Ophthalmology 1999; 106: 1915–1923
- Arnold J J, Blinder K J, Bressler N M, Bressler S B, Burdan A, Haynes L, Lim J I, Miller J W, Potter M J, Reaves A, Rosenfeld P J, Sickenberg M, Slakter J S, Soubrane G, Strong H A, Stur M. Acute severe visual acuity decrease after photodynamic therapy with verteporfin: case reports from randomized clinical trials-TAP and VIP report no. 3. Am J Ophthalmol 2004; 137: 683–696
- Renno R Z, Terada Y, Haddadin M J, Michaud N A, Gragoudas E S, Miller J W. Selective photodynamic therapy by targeted verteporfin delivery to experimental choroidal neovascularization mediated by a homing peptide to vascular endothelial growth factor receptor-2. Arch Ophthalmol 2004; 122: 1002–1011
- Van d en, Bergh H, Ballini J P, Sickenberg M. On the selectivity of photodynamic therapy of choroidal neovascularization associated with age-related macular degeneration. J Fr Ophtalmol 2004; 27: 75–78
- Gragoudas E S, Adamis A P, Cunningham E T, Jr., Feinsod M, Guyer D R. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351: 2805–2816
- Hicklin D J, Ellis L M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23: 1011–1027
- Van Wijngaarden P, Coster D J, Williams K A. Inhibitors of ocular neovascularization: promises and potential problems. J Am Med Assoc 2005; 293: 1509–1513
- Hu Z, Sun Y, Garen A. Targeting tumor vasculature endothelial cells and tumor cells for immunotherapy of human melanoma in a mouse xenograft model. Proc Natl Acad Sci USA 1999; 96: 8161–8166
- Callander N S, Varki N, Rao L V. Immunohistochemical identification of tissue factor in solid tumors. Cancer 1992; 70: 1194–1201
- Drake T A, Morrissey J H, Edgington T S. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol 1989; 134: 1087–1097
- Flossel C, Luther T, Muller M, Albrecht S, Kasper M. Immunohistochemical detection of tissue factor (TF) on paraffin sections of routinely fixed human tissue. Histochemistry 1994; 101: 449–453
- Hu Z, Garen A. Targeting tissue factor on tumor vascular endothelial cells and tumor cells for immunotherapy in mouse models of prostatic cancer. Proc Natl Acad Sci USA 2001; 98: 12180–12185
- Bora P S, Hu Z, Tezel T H, Sohn J H, Kang S G, Cruz J M, Bora N S, Garen A, Kaplan H J. Immunotherapy for choroidal neovascularization in a laser-induced mouse model simulating exudative (wet) macular degeneration. Proc Natl Acad Sci USA 2003; 100: 2679–2684
- Luchtel D L, Boykin J C, Bernard S L, Glenny R W. Histological methods to determine blood flow distribution with fluorescent microspheres. Biotech Histochem 1998; 73: 291–309
- Wagner D D. Cell biology of von Willebrand factor. Annu Rev Cell Biol 1990; 6: 217–246
- Collins C J, Underdahl J P, Levene R B, Ravera C P, Morin M J, Dombalagian M J, Ricca G, Livingston D M, Lynch D C. Molecular cloning of the human gene for von Willebrand factor and identification of the transcription initiation site. Proc Natl Acad Sci USA 1987; 84: 4393–4397